Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Enzalutamide + EPI-7386 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EPI-7386 | EPI7386|EPI 7386 | Hormone - Anti-androgens 40 | EPI-7386 is an N-terminal domain AR inhibitor that blocks transcriptional activity of both full-length and splice variants of AR, potentially leading to antitumor effects (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B117). | |
Enzalutamide | Xtandi | MDV3100|ASP9785 | Hormone - Anti-androgens 40 | Xtandi (enzalutamide) is a second-generation small molecule androgen receptor (AR) inhibitor that inhibits AR signaling, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). Xtandi (enzalutamide) is FDA approved for use in patients with castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05075577 | Phase Ib/II | Enzalutamide + EPI-7386 Enzalutamide | EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC | Recruiting | USA | CAN | 0 |